(Q36767051)

16 August 2017

1 reference

title

Immunosuppressive therapy for primary biliary cirrhosis (English)

1 reference

16 August 2017

Immunosupressive therapy for primary biliary cirrhosis (English)

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

primary biliary cholangitis

12 November 2022

main subject

0 references

author name string

R. Beukers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1737909

12 November 2022

S. W. Schalm

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1737909

12 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1737909

12 November 2022

publication date

1 January 1992

1 reference

full work available at URL

16 August 2017

https://api.elsevier.com/content/article/PII:0168827892901237?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

https://api.elsevier.com/content/article/PII:0168827892901237?httpAccept=text/plain

12 November 2022

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

12 November 2022

published in

Journal of Hepatology

1 reference

16 August 2017

volume

14

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

1-6

1 reference

Primary biliary cirrhosis

16 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

NIH conference: Primary biliary cirrhosis: a model autoimmune disease

12 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Suppressor cell activity in primary biliary cirrhosis

12 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis

12 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of enterobacteriaceae?

12 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis

12 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis

12 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis

12 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

D-penicillamine treatment improves survival in primary biliary cirrhosis

12 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A prospective trial of D-penicillamine in primary biliary cirrhosis

12 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis

12 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Trial of penicillamine in advanced primary biliary cirrhosis

12 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

12 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis

12 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A prospective trial of colchicine for primary biliary cirrhosis

12 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Evaluation of colchicine therapy in primary biliary cirrhosis

12 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report

12 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Randomized trial of chlorambucil for primary biliary cirrhosis.

12 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

12 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

12 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis

12 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Review: the treatment of primary biliary cirrhosis.

12 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

12 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Efficacy of liver transplantation in patients with primary biliary cirrhosis

12 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

D-penicillamine for primary biliary cirrhosis.

12 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease

12 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study

12 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Cyclosporine: a new immunosuppressive agent for organ transplantation

12 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Cyclosporine nephrotoxicity

12 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years

12 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

12 November 2022

Cyclosporine

43

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Renal histopathologic alterations in patients treated with cyclosporine for uveitis

12 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids

12 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Osteoporosis and skeletal fractures in chronic liver disease

12 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids

12 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Methotrexate treatment of chronic cholestatic liver diseases: friend or foe?

12 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio

12 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

12 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature

12 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

12 November 2022

56

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

12 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

12 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

FK 506: an immunosuppressant for the 1990s?

12 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

12 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/0168-8278(92)90123-7

12 November 2022

Identifiers

1 reference

16 August 2017

1 reference